Fredag 27 December | 20:15:06 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-04-24 08:00 Kvartalsrapport 2025-Q1
2025-02-13 17:30 Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning ATORX 0.00 SEK
2024-05-07 - Årsstämma
2024-05-06 - Kvartalsrapport 2024-Q1
2024-03-14 - Extra Bolagsstämma 2024
2024-02-09 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-05-26 - Årsstämma
2023-05-04 - X-dag ordinarie utdelning ATORX 0.00 SEK
2023-04-25 - Kvartalsrapport 2023-Q1
2023-04-14 - Extra Bolagsstämma 2022
2023-02-10 - Bokslutskommuniké 2022
2022-10-20 - Kvartalsrapport 2022-Q3
2022-07-12 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning ATORX 0.00 SEK
2022-05-05 - Årsstämma
2022-04-27 - Kvartalsrapport 2022-Q1
2022-02-11 - Bokslutskommuniké 2021
2021-11-08 - Extra Bolagsstämma 2021
2021-10-21 - Kvartalsrapport 2021-Q3
2021-07-13 - Kvartalsrapport 2021-Q2
2021-06-01 - Årsstämma
2021-05-03 - X-dag ordinarie utdelning ATORX 0.00 SEK
2021-04-27 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-10-22 - Kvartalsrapport 2020-Q3
2020-07-13 - Kvartalsrapport 2020-Q2
2020-05-06 - X-dag ordinarie utdelning ATORX 0.00 SEK
2020-05-05 - Årsstämma
2020-04-23 - Kvartalsrapport 2020-Q1
2020-02-12 - Bokslutskommuniké 2019
2019-10-24 - Kvartalsrapport 2019-Q3
2019-07-11 - Kvartalsrapport 2019-Q2
2019-05-10 - X-dag ordinarie utdelning ATORX 0.00 SEK
2019-05-09 - Årsstämma
2019-04-17 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018
2018-10-26 - Kvartalsrapport 2018-Q3
2018-07-12 - Kvartalsrapport 2018-Q2
2018-04-27 - X-dag ordinarie utdelning ATORX 0.00 SEK
2018-04-26 - Årsstämma
2018-04-26 - Kvartalsrapport 2018-Q1
2018-02-16 - Bokslutskommuniké 2017
2017-10-25 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-05-03 - X-dag ordinarie utdelning ATORX 0.00 SEK
2017-05-02 - Årsstämma
2017-05-02 - Kvartalsrapport 2017-Q1
2017-02-17 - Bokslutskommuniké 2016
2016-11-14 - Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Alligator Bioscience är ett forskningsbaserat bioteknikbolag. Bolaget använder en patenterad teknologi för att utveckla biologiska läkemedelskandidater inom inflammation och cancer, och är verksamt i den tidigare delen av läkemedelsutvecklingskedjan. Alligator Bioscience har en global teknologiplattform och är aktivt inom ett snabbt växande segment på läkemedelsmarknaden – proteinläkemedel. Bolaget grundades år 2001 och har sitt huvudkontor i Lund.
2024-03-15 11:00:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

The Board of Directors of Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has prepared a prospectus (the “Prospectus”) in connection with the rights issue of units of approximately SEK 150.9 million which was resolved by the Board of Directors on February 8, 2024, and approved by the Extraordinary General Meeting held on March 14, 2024 (the “Rights Issue”). The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.

Summary

  • The Rights Issue comprises a maximum of 140,990,205 units where each unit consists of one (1) ordinary share and one (1) warrant series TO 9 free of charge.
  • One (1) existing ordinary share in the Company on the record date entitles to three (3) unit rights. Fourteen (14) unit rights entitle to subscription of one (1) unit.
  • One (1) warrant series TO 9 will entitle the holder to subscribe for one (1) new ordinary share in the Company.
  • The subscription price is SEK 1.07 per unit, corresponding to SEK 1.07 per ordinary share, which, assuming that the Rights Issue is fully subscribed, results in the Company initially receiving proceeds of approximately SEK 150.9 million before issue costs.
  • If the Rights Issue is oversubscribed, the Board of Directors of the Company may carry out an over-allotment issue of a maximum of 93,457,944 units, corresponding to initially approximately SEK 100.0 million before issue costs, directed to investors who have subscribed for units in the Rights Issue without receiving full allotment (the “Over-Allotment Issue”). The subscription price in the Over-Allotment Issue will be the same as in the Rights Issue.
  • Major shareholders have expressed their support for the Rights Issue through subscription undertakings amounting to approximately SEK 59.8 million, corresponding to approximately 40 percent of the Rights Issue.

Complete terms and conditions for the Rights Issue and the Over-Allotment Issue are available in the Prospectus published by the Company on its website, www.alligatorbioscience.se/en.

The Prospectus
The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on March 15, 2024, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, is available on the Company's and Vator Securities AB's respective websites (www.alligatorbioscience.se/en, www.vatorsecurities.se). The Prospectus will also be available on the Swedish Financial Supervisory Authority's website (www.fi.se). Subscription forms will be available on the Company's and Vator Securities AB’s respective websites.

Timetable for the Rights Issue

March 15, 2024Publication of the Prospectus
March 15, 2024Last day of trading incl. preferential rights
March 18, 2024First day of trading excl. preferential rights
March 19, 2024Record date in the Rights Issue
March 21, 2024 – April 2, 2024Trading in unit rights
March 21, 2024 – April 5, 2024Subscription period
March 21, 2024 – April 25, 2024Trading in paid subscribed units (“BTU”)
Around April 9, 2024Estimated publication of outcome in the Rights Issue and potential exercise of the Over-Allotment Issue

Advisers
Vator Securities AB acts as Sole Global Coordinator and bookrunner in connection with the Rights Issue and Van Lanschot Kempen N.V. acts as financial adviser to Alligator in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.